Tag - HOOK

Developments

HOOKIPA completes enrollment in Phase 1b study of HB-500 in HIV

HOOKIPA Pharma (NASDAQ:HOOK) has announced the completion of enrollment for its Phase 1b trial evaluating HB-500 in patients with HIV. The company stated that the study is comprised of two dose-escalation cohorts, with...

January 30, 2025

Developments

HOOKIPA doses first patient in Phase 2 trial of eseba-vec for head and neck cancer

HOOKIPA Pharma (NASDAQ:HOOK) has announced that the first patient has been dosed in an investigator-initiated trial (IIT) of eseba-vec as adjunct therapy for patients with minimal residual disease-positive, HPV-driven...

October 30, 2024

Markets

HCW starts Hookipa Pharma at buy; PT $15

H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its proprietary family...

September 27, 2019

Tag - HOOK

HOOKIPA completes enrollment in Phase 1b study of HB-500 in HIV

HOOKIPA doses first patient in Phase 2 trial of eseba-vec for head and neck cancer

HCW starts Hookipa Pharma at buy; PT $15

Subscribe